

Yu Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7781030/publications.pdf>

Version: 2024-02-01

126
papers

5,412
citations

116194

36
h-index

116156

66
g-index

127
all docs

127
docs citations

127
times ranked

3129
citing authors

#	ARTICLE	IF	CITATIONS
1	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2022, 36, 267-270.	3.3	14
2	Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. <i>British Journal of Haematology</i> , 2022, 196, 735-742.	1.2	3
3	Donor activating killer cell immunoglobulin-like receptors genes correlated with Epstein-Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2022, 196, 1007-1017.	1.2	4
4	Preemptive Interferon- γ Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. <i>Frontiers in Immunology</i> , 2022, 13, 757002.	2.2	13
5	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072110728.	1.1	8
6	Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy. <i>American Journal of Hematology</i> , 2022, 97, 762-769.	2.0	14
7	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 862526.	1.8	7
8	Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. <i>Journal of Hematology and Oncology</i> , 2022, 15, 22.	6.9	24
9	The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
10	Combination of <i>KIT</i> and <i>FLT3-ITD</i> mutation status with minimal residual disease levels guides treatment strategy for adult patients with <i>inv(16)</i> acute myeloid leukemia in first complete remission. <i>Hematological Oncology</i> , 2022, 40, 724-733.	0.8	2
11	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1204-1206.	1.3	5
12	Prevalence and risk factors of antibodies to HLA according to different cutoff values of mean fluorescence intensity in haploidentical allograft candidates: A prospective study of 3805 subjects. <i>Hla</i> , 2022, 100, 312-324.	0.4	6
13	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. <i>Annals of Hematology</i> , 2021, 100, 169-180.	0.8	14
14	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. <i>Clinical Transplantation</i> , 2021, 35, e14160.	0.8	12
15	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. <i>Annals of Hematology</i> , 2021, 100, 799-808.	0.8	2
16	Pretransplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. <i>Cancer Communications</i> , 2021, 41, 333-344.	3.7	5
17	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. <i>Frontiers in Oncology</i> , 2021, 11, 631625.	1.3	8
18	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1267-1281.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. <i>Leukemia</i> , 2021, 35, 3092-3100.	3.3	22
20	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 67.	2.8	9
21	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. <i>Science Bulletin</i> , 2021, 66, 2498-2505.	4.3	44
22	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 2723-2731.	1.3	4
23	Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. <i>JAMA Network Open</i> , 2021, 4, e2115991.	2.8	12
24	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 668.e1-668.e9.	0.6	3
25	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 749266.	2.2	12
26	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. <i>Annals of Hematology</i> , 2021, 100, 555-562.	0.8	5
27	Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph ⁺ high-risk B-cell acute lymphoblastic leukemia. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	0.9	4
28	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2021, 11, 773394.	1.3	8
29	Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 195.	2.8	8
30	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 70, 1429-1437.	2.9	30
31	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). <i>Science China Life Sciences</i> , 2020, 63, 571-581.	2.3	26
32	Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. <i>British Journal of Haematology</i> , 2020, 189, 153-161.	1.2	8
33	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 351-357.	2.0	20
34	Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. <i>Leukemia</i> , 2020, 34, 1433-1443.	3.3	73
35	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. <i>Pediatric Transplantation</i> , 2020, 24, e13864.	0.5	5
36	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2020, 22, 755-761.	0.3	33

#	ARTICLE	IF	CITATIONS
37	Preemptive interferon- γ treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. <i>Scientific Reports</i> , 2020, 10, 20148.	1.6	7
38	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1201-1212.	5.1	209
39	The incidence, risk factors, and outcomes of acute graft-versus-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2020, 24, e13793.	0.5	1
40	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1655-1662.	2.0	8
41	Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. <i>Bone Marrow Transplantation</i> , 2020, 55, 1326-1336.	1.3	31
42	Haploidentical-versus identical-sibling transplant for high-risk pediatric AML: A multicenter study. <i>Cancer Communications</i> , 2020, 40, 93-104.	3.7	20
43	Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. <i>Journal of Hematology and Oncology</i> , 2020, 13, 18.	6.9	36
44	Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graft-versus-host disease for young donors. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9204-9216.	1.6	2
45	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. <i>Science China Life Sciences</i> , 2020, 63, 1261-1264.	2.3	8
46	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. <i>Science China Life Sciences</i> , 2020, 63, 1552-1564.	2.3	12
47	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1452-1458.	2.0	10
48	A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2649-2657.	0.8	2
49	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting V γ 2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18
50	Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute <sc>graft-versus-host disease</sc>: Updated experience from a large-scale study. <i>American Journal of Hematology</i> , 2020, 95, 927-936.	2.0	32
51	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 27.	6.9	48
52	Modification of donor lymphocyte infusion: how to improve the outcome?. <i>Science China Life Sciences</i> , 2019, 62, 1253-1256.	2.3	6
53	Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. <i>BMC Medicine</i> , 2019, 17, 156.	2.3	55
54	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 88.	6.9	76

#	ARTICLE	IF	CITATIONS
55	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. <i>Journal of Hematology and Oncology</i> , 2019, 12, 87.	6.9	24
56	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. <i>American Journal of Hematology</i> , 2019, 94, 512-521.	2.0	51
57	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1319-1326.	1.3	35
58	G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1419-1433.	1.3	40
59	Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1694-1700.	1.3	9
60	Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Engineering</i> , 2019, 5, 150-155.	3.2	8
61	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1210-1217.	2.0	2
62	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. <i>Blood Advances</i> , 2019, 3, 1303-1317.	2.5	43
63	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4312-4325.	2.5	27
64	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. <i>Science China Life Sciences</i> , 2019, 62, 691-697.	2.3	16
65	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <i>Clinical Cancer Research</i> , 2019, 25, 1737-1748.	3.2	26
66	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. <i>British Journal of Haematology</i> , 2019, 184, 788-796.	1.2	8
67	Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1287-1294.	1.3	7
68	N-acetylcysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia postallotransplant. <i>British Journal of Haematology</i> , 2018, 180, 863-878.	1.2	22
69	Inverse correlation of γ 2+ α cell recovery with EBV reactivation after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 276-285.	1.2	23
70	First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. <i>Clinical Transplantation</i> , 2018, 32, e13179.	0.8	29
71	Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. <i>Science China Life Sciences</i> , 2018, 61, 569-577.	2.3	8
72	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. <i>Chinese Medical Journal</i> , 2018, 131, 2185-2192.	0.9	5

#	ARTICLE	IF	CITATIONS
73	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. <i>Cancer Letters</i> , 2018, 438, 63-75.	3.2	116
74	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. <i>Science Bulletin</i> , 2018, 63, 1376-1382.	4.3	27
75	An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 679-692.	1.2	36
76	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). <i>Blood Cancer Journal</i> , 2018, 8, 76.	2.8	21
77	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. <i>Human Immunology</i> , 2018, 79, 672-677.	1.2	11
78	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 44.	6.9	51
79	Viral encephalitis after haploidentical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. <i>European Journal of Haematology</i> , 2017, 98, 450-458.	1.1	22
80	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease—Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1311-1319.	2.0	66
81	IFN- γ Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1303-1310.	2.0	40
82	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 829-838.	0.8	39
83	Donor-derived CD^{19} -targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 179, 598-605.	1.2	87
84	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. <i>Oncolimmunology</i> , 2017, 6, e1356152.	2.1	28
85	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2017, 216, 945-956.	1.9	82
86	Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. <i>American Journal of Hematology</i> , 2017, 92, E659-E661.	2.0	19
87	Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2017, 179, 120-130.	1.2	70
88	Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	21
89	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 134.	6.9	132
90	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2143-2150.	2.0	19

#	ARTICLE	IF	CITATIONS
91	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. <i>European Journal of Haematology</i> , 2016, 96, 297-308.	1.1	37
92	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2016, 22, 3467-3476.	3.2	142
93	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 1855-1863.	0.8	100
94	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2235-2242.	2.0	11
95	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. <i>Science China Life Sciences</i> , 2016, 59, 1139-1148.	2.3	13
96	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. <i>Oncolmmunology</i> , 2016, 5, e1250992.	2.1	21
97	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. <i>Journal of Hematology and Oncology</i> , 2016, 9, 87.	6.9	57
98	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 2016, 139, 2106-2115.	2.3	47
99	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. <i>Oncolmmunology</i> , 2016, 5, e1242546.	2.1	11
100	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. <i>Journal of Clinical Virology</i> , 2016, 75, 10-15.	1.6	21
101	Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 391-397.	1.3	54
102	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. <i>Clinical Transplantation</i> , 2015, 29, 523-530.	0.8	14
103	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2015, 13, 391.	1.8	24
104	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte-colony-stimulating factor-mobilized marrow harvests and peripheral blood harvests. <i>Transfusion</i> , 2015, 55, 2874-2881.	0.8	18
105	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. <i>Blood</i> , 2015, 125, 3956-3962.	0.6	387
106	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3116-3123.	0.6	31
107	Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2185-2191.	2.0	46
108	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. <i>Journal of Hematology and Oncology</i> , 2015, 8, 84.	6.9	160

#	ARTICLE	IF	CITATIONS
109	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high- and low-risk groups. <i>International Journal of Cancer</i> , 2015, 136, 1697-1707.	2.3	42
110	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , 2014, 38, 1435-1440.	0.4	63
111	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia-Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 929-936.	2.0	28
112	Haploidentical stem cell transplantation for the treatment of leukemia: current status. <i>Expert Review of Hematology</i> , 2014, 7, 635-647.	1.0	24
113	Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2023-2028.	2.0	25
114	Who is the best donor for a related HLA haplotype-mismatched transplant?. <i>Blood</i> , 2014, 124, 843-850.	0.6	285
115	In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. <i>Blood</i> , 2014, 124, 1880-1886.	0.6	106
116	Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. <i>Cancer</i> , 2013, 119, 978-985.	2.0	224
117	Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1465-1473.	2.0	114
118	Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 283-290.	2.0	36
119	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013, 121, 4056-4062.	0.6	277
120	Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 3256-3262.	0.6	264
121	Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 716-721.	2.0	24
122	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. <i>Blood</i> , 2012, 119, 5584-5590.	0.6	107
123	Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multicenter study. <i>Clinical Transplantation</i> , 2012, 26, 635-643.	0.8	56
124	Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 821-830.	2.0	149
125	Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia. <i>Journal of Clinical Immunology</i> , 2008, 28, 276-283.	2.0	66
126	Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2